The consortium also includes Exonhit, InGen BioSciences, AP-HP (Paris Public Hospitals), Inserm (National Institute for medical research), and Paris-Diderot University. It aims at developing innovative therapies for the enzymatic treatment of chemo- or radio-resistant cancers, and accompanying tools to identify responders and enable personalized care of patients. The project, endorsed by the Competitiveness Cluster Lyonbiopôle, will run over 8 years. The total amount of support awarded to the consortium amounts to approximately €10.7 million.
ERYTECH is developing a new approach to fight cancer by starving tumors through depleting specific amino acids, needed for the tumor growth, from their metabolic environment. Weakening tumors by acting on their environment is synergic with classical chemotherapy drugs